Navigation Links
New inhibitor has potential as cancer drug
Date:10/22/2007

Laboratory experiments have previously shown that cancer cells overproduce an enzyme, heparanase, which splits the bodys own polysaccharide heparan sulfate into shorter fragments. The amount of enzyme is related to the degree of malignancy. Today a study is being published in the journal Nature Chemical Biology in which Uppsala University researchers show, on the basis of animal models, that an inhibitor for heparanase would be extremely interesting as a drug candidate.

Heparan sulfate is a polysaccharide, that is, a chain of linked sugar units, with sulfate groups in different positions. These chains are found on the surface of practically every cell in the body. The sulfate groups enable binding to a number of proteins, such as inflammation proteins and growth factors. Heparan sulfate can thereby regulate different processes in the body, during embryonic development, for example, but also in various conditions of sickness. The capacity for protein-binding generally increases the more sulfate groups there are on the polysaccharide.

The enzyme heparanase splits heparan sulfate at certain points and converts the long chains into shorter fragments. Research at other laboratories has shown that cancer cells in many cases overproduce heparanase and that the amount of heparanase correlates with the degree of malignancy of the cancer cells and their capacity to metasthesize. The connection is believed to have multiple explanations. Heparanase helps cancer cells make their way through tissue barriers, but it also stimulates the heightened generation of blood vessels that is necessary for tumor growth. The fragments function as carriers of growth factors that can promote tumor growth in many ways.

In the current project the scientists introduced the gene for human heparanase into a mouse, so that the enzyme would be overproduced in several organs. Besides the expected splitting of heparan sulfate, they found that the metabolism of t
'/>"/>

Contact: Jin-ping Li
Jin-ping.Li@imbim.uu.se
46-018-471-4241
Uppsala University
Source:Eurekalert

Page: 1 2

Related biology news :

1. HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs
2. Breast Cancer May Be Uniquely Sensitive To Inhibitors Of PI3K Pathway
3. Anthrax inhibitors identified by Burnham team
4. Protease inhibitors reach beyond HIV
5. UNC scientists discover new role for protein as fundamental inhibitor of cell movement
6. Small molecule inhibitor of cholera discovered
7. Enzyme inhibitors block replication of SARS virus
8. Scientists design potent anthrax toxin inhibitor
9. Sweet water taste paradoxically predicts sweet taste inhibitors
10. Anthrax inhibitor counteracts toxin, may lead to new therapeutics
11. COX-2 inhibitors significantly reduce risk of cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... such as buying clothing not made in a sweat ... their own bags when they go shopping? According to ... Research , ethical consumption is motivated by a need ... into action. , "Advocates of ethical consumerism suggest that ... the products they choose, but unfortunately only a small ...
(Date:9/16/2014)... Sept. 16, 2014  Cross Match Technologies, a ... announced today the launch of its Verifier ® ... identity of an individual using their secure credentials ... rapidly reads credential documents with embedded biometric data ... the biometric to a live scan of their ...
(Date:9/15/2014)... (September 15, 2014) The so-called central dogma ... proteinhas long provided a simplified explanation for how ... organisms. , In reality, of course, the ... first articulated nearly 60 years ago by Nobel ... structure. For one, there are multiple types of ...
Breaking Biology News(10 mins):Why are consumers willing to spend more money on ethical products? 2Cross Match Launches New Identity Management Handheld Solution 2Scientists discover RNA modifications in some unexpected places 2
... discovery by UNC scientists describes how cells infected by ... called exosomes, changing their cellular "cargo" of proteins and ... the growth of recipient cells from benign to cancer-producing. ... effects and potentially manipulate other cells throughout the body. ...
... University of California, San Diego School of Medicine and ... approved drugs to more than 1,000 proteins in Mycobacterium ... avenues to repurpose these drugs to treat TB. ... Computational Biology . "Tuberculosis is currently one of ...
... study by researchers at the Johns Hopkins Bloomberg School of ... disease among male clients of the commercial sex industry in ... drug use as the primary transmission mode of all HIV ... of publication in the journal Sexually Transmitted Infections . ...
Cached Biology News:UNC scientists identify cellular communicators for cancer virus 2TB-drugome provides new targets for anti-tuberculosis drug discovery 2Study examines risk of heterosexual HIV transmission in China 2
(Date:9/16/2014)... 16, 2014 “Nature has developed, very ... that we desire in optical design,” said Joseph Shaw, ... University. “As we explore surfaces and structures at the ... were presented in San Diego in August during a ... Nature ” chaired by Shaw and Rongguang Liang of ...
(Date:9/16/2014)... phones to cars and flashlights, batteries play an ... companies constantly are seeking ways to improve battery ... using a water-based solution, researchers at the University ... efficient nuclear battery that could be used for ... in automobiles and also in complicated applications such ...
(Date:9/16/2014)... MA (PRWEB) September 16, 2014 CIRTEC ... of Brian Highley as CEO of CIRTEC. , ... exciting point for the Company.” noted Brian Highley. “The ... performance while sustaining strong organic growth over the past ... growth by continuing to improve and expand the services ...
(Date:9/16/2014)...  LABSCO, the leading specialty sales agent of ... office laboratories and alternate healthcare settings is proud ... will serve as Siemens Healthcare Diagnostics, exclusive sales ... a semi-exclusive sales distributor in specified POL market ... States . LABSCO will be responsible for ...
Breaking Biology Technology:Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3
... engine dedicated to recruiting exceptional talent to jobs at ... the most rewarding careers on the planet, but they ... StartUpHire website, www.startuphire.com , lists thousands of jobs ... investor, and more. Search agents allow users to ...
... (Pink Sheets: SYNJ), Reports that it has engaged in ... The job of the Director will be to coordinate ... Pinnacle Energy Division. The Company is currently considering ventures ... production, and microwave plasma physics. To that end, the ...
... NOVATO, Calif., March 18 BioMarin Pharmaceutical Inc. (Nasdaq: ... for clinical trial authorization (CTA) for BMN 110 or ... lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or ... Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA). BioMarin ...
Cached Biology Technology:StartUpHire Launches Comprehensive Search Engine for Jobs at Venture-Backed Companies 2StartUpHire Launches Comprehensive Search Engine for Jobs at Venture-Backed Companies 3Syndication Inc. Seeks 'DIRECTOR OF TECHNICAL ENGINEERING' for 'PINNACLE ENERGY' - Its New Alternative Energy Subsidiary 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 3BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 4